一项研究,研究Ronde-Cel与研究者的选择CD19 CAR T细胞疗法 (PiNACLE-H2H)
Rondecabtagene Autoleucel的3阶段随机对照试验,这是一种自体,双靶标CD19/CD20 CAR T细胞产品候选,与研究者在第二线环境中的复发或耐火性大B-Cell淋巴瘤患者相对于研究者选择CD19 CD19 CAR T-Cell治疗
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
研究概览
地位
条件
详细说明
PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20 antibody and anthracycline-containing chemotherapy.
Patients will be randomized (1:1) before leukapheresis to receive either:
- Ronde-cel; or
- Investigator's choice of axi-cel or liso-cel
Most patients who receive currently approved CD19-directed CAR T-cell therapies, including axi-cel and liso-cel, still experience progressive disease, often due to mechanisms such as CD19 antigen loss or T-cell exhaustion.
Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate enriched for CD62L-positive naïve and central memory T cells, which are associated with enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct that can fully activate upon recognition of either CD19 or CD20, aiming to improve durability of response despite antigen heterogeneity.
Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be administered as a single intravenous infusion following fludarabine and cyclophosphamide lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with long-term follow-up extending to 15 years.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Mary Lessig, MS
- 电话号码:000-000-0000
- 邮箱:clinicaltrials@lyell.com
研究联系人备份
- 姓名:James Dean, MD, PhD
- 电话号码:000-000-0000
- 邮箱:clinicaltrials@lyell.com
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2C4
- 招聘中
- Princess Margaret Cancer Centre
-
-
-
-
Queensland
-
Douglas、Queensland、澳大利亚、4814
- 招聘中
- Townsville University Hospital
-
-
Victoria
-
Melbourne、Victoria、澳大利亚、3004
- 招聘中
- The Alfred
-
-
-
-
Arizona
-
Gilbert、Arizona、美国、85234
- 招聘中
- Banner MD Anderson Cancer Center
-
Scottsdale、Arizona、美国、85258
- 招聘中
- Honor Health
-
Scottsdale、Arizona、美国、85259
- 招聘中
- Mayo Clinic Arizona
-
-
Arkansas
-
Little Rock、Arkansas、美国、72205
- 尚未招聘
- University of Arkansas
-
-
California
-
Los Angeles、California、美国、90048
- 招聘中
- Cedars-Sinai Medical Center
-
Los Angeles、California、美国、90095
- 招聘中
- University of California, Los Angeles (UCLA)
-
Orange、California、美国、92868
- 招聘中
- University of California, Irvine
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- University of Colorado
-
Denver、Colorado、美国、80218
- 招聘中
- Colorado Blood Cancer Institute
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20007
- 招聘中
- MedStar Georgetown University Hospital
-
-
Florida
-
Jacksonville、Florida、美国、32224
- 招聘中
- Mayo Clinic Florida
-
Orlando、Florida、美国、32804
- 招聘中
- AdventHealth
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta、Georgia、美国、30342
- 招聘中
- Northside Hospital
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago
-
Chicago、Illinois、美国、60611
- 招聘中
- Northwestern
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- 招聘中
- University of Iowa
-
-
Kansas
-
Westwood、Kansas、美国、66205
- 招聘中
- University of Kansas Cancer Center
-
-
Kentucky
-
Louisville、Kentucky、美国、40202
- 招聘中
- University of Louisville Health
-
-
Massachusetts
-
Boston、Massachusetts、美国、02111
- 招聘中
- Tufts Medical Center
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha、Nebraska、美国、68105
- 招聘中
- University of Nebraska Medical Center (UNMC)
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- 招聘中
- Hackensack
-
Morristown、New Jersey、美国、07960
- 招聘中
- Atlantic Health
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87102
- 招聘中
- University of New Mexico Comprehensive Cancer Center
-
-
New York
-
Buffalo、New York、美国、14263
- 招聘中
- Roswell Park Comprehensive Cancer Center
-
-
North Carolina
-
Durham、North Carolina、美国、27705
- 招聘中
- Duke Cancer Institute
-
Winston-Salem、North Carolina、美国、27157
- 尚未招聘
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati、Ohio、美国、45267
- 招聘中
- University of Cincinnati
-
Cincinnati、Ohio、美国、45242
- 招聘中
- Oncology Hematology Care Clinical Trials
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinical Taussig Cancer Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15212
- 尚未招聘
- Allegheny Health Network
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- SCRI Oncology Partners
-
-
Texas
-
Austin、Texas、美国、78704
- 招聘中
- St. David's South Austin Medical Center
-
Fort Worth、Texas、美国、76104
- 招聘中
- University of Texas Southwestern Medical Center
-
Houston、Texas、美国、77030
- 招聘中
- MD Anderson Cancer Center
-
San Antonio、Texas、美国、78229
- 招聘中
- Texas Transplant Institute
-
-
Utah
-
Salt Lake City、Utah、美国、84143
- 招聘中
- Intermountain Healthcare
-
-
Virginia
-
Norfolk、Virginia、美国、23502
- 招聘中
- Virginia Oncology Associates
-
Richmond、Virginia、美国、23298
- 招聘中
- Virginia Commonwealth University-Massey Cancer Center
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- 招聘中
- Medical College of Wisconsin
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
-
Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
- Diffuse large B-cell lymphoma (DLBCL)
- Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
- DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
- High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
-
Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
-
Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
-
Adequate hematological, renal, hepatic, pulmonary, and cardiac function
Key Exclusion Criteria:
- Patients ineligible to receive CD19 CAR T-cell therapy
- Primary CNS lymphoma
- Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
- Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
- Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
- Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.
Note: Other protocol defined Inclusion/Exclusion criteria may apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Rondecabtagene自动赛
|
An autologous, dual-targeting CD19/20 CAR T-cell candidate.
其他名称:
|
|
有源比较器:Investigator's Choice CD19
axicabtagene ciloleucel, lisocabtagene maraleucel |
An autologous CD19 CAR T-cell therapy
其他名称:
An autologous CD19 CAR T-cell therapy
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Event free survival
大体时间:36 months
|
The time interval from treatment initiation until the occurrence of a specific event of interest. |
36 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Response Rate
大体时间:36 months
|
Best Overall Response per Lugano Criteria |
36 months
|
|
Complete Response Rate
大体时间:36 months
|
Complete Response per Lugano Criteria |
36 months
|
|
Progression Free Survial
大体时间:36 months
|
The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. |
36 months
|
|
Overall Survival
大体时间:6 years
|
The length of time from either the date of diagnosis or the start of treatment for a disease, that patients diagnosed with the disease, are still alive. |
6 years
|
|
Incidence and severity adverse events
大体时间:36 months
|
To assess safety defined as type and frequency of AEs, serious adverse events (SAEs), and laboratory abnormalities. |
36 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.